Remove Clinical Development Remove DNA Remove Licensing Remove Pharma Companies
article thumbnail

Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal

pharmaphorum

The new deal will assists the company’s focus “on advancing and innovating Parexel to meet our customers’ needs across the evolving clinical development landscape,” he added. ” The deal is subject to the usual conditions, including receipt of various approvals from regulators around the world.

article thumbnail

Are radiopharmaceuticals the next breakthrough in oncology?

pharmaphorum

However, there is a difference between the two: the toxic payloads of ADCs need to be absorbed into cancer cells, whereas radiopharmaceuticals can still do damage even when only bound to the cancer, and are particularly sensitive to radiation-induced DNA damage. Investment is flowing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

Dr Tralau-Stewart says: “Indeed, many academic institutions have established new ways of supporting the discovery pipeline, providing tech transfer offices to support licensing, and entrepreneurship and start-up support through fundraising, accelerators, and incubators.

Drugs 75
article thumbnail

New horizon for cancer innovation

Drug Discovery World

RA: How can the integration of industry and academia help streamline drug development? . TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out.

HR 52
article thumbnail

Touchlight boosts DNA manufacturing capacity with latest expansion

Pharmaceutical Technology

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130
article thumbnail

AstraZeneca Closes in on Potential UK Vaccine Authorization and Other COVID-19 News

The Pharma Data

the company is exploring other ways to combat COVID-19. AstraZeneca is partnering with INOVIO and multiple universities to advance INOVIO’s innovative DNA-encoded monoclonal antibody (dMAb) technology. and will leverage a major COVID-19 vaccine partnership the company struck with the U.K. The study will be conducted in the U.K.